1. Home
  2. HOWL vs TLSA Comparison

HOWL vs TLSA Comparison

Compare HOWL & TLSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • HOWL
  • TLSA
  • Stock Information
  • Founded
  • HOWL 2017
  • TLSA 2013
  • Country
  • HOWL United States
  • TLSA United Kingdom
  • Employees
  • HOWL N/A
  • TLSA N/A
  • Industry
  • HOWL Biotechnology: Pharmaceutical Preparations
  • TLSA Biotechnology: Pharmaceutical Preparations
  • Sector
  • HOWL Health Care
  • TLSA Health Care
  • Exchange
  • HOWL Nasdaq
  • TLSA Nasdaq
  • Market Cap
  • HOWL 87.4M
  • TLSA 87.8M
  • IPO Year
  • HOWL 2021
  • TLSA 2000
  • Fundamental
  • Price
  • HOWL $1.45
  • TLSA $0.88
  • Analyst Decision
  • HOWL Strong Buy
  • TLSA
  • Analyst Count
  • HOWL 2
  • TLSA 0
  • Target Price
  • HOWL $9.50
  • TLSA N/A
  • AVG Volume (30 Days)
  • HOWL 260.1K
  • TLSA 1.1M
  • Earning Date
  • HOWL 03-06-2025
  • TLSA 02-25-2025
  • Dividend Yield
  • HOWL N/A
  • TLSA N/A
  • EPS Growth
  • HOWL N/A
  • TLSA N/A
  • EPS
  • HOWL N/A
  • TLSA N/A
  • Revenue
  • HOWL $3,386,000.00
  • TLSA N/A
  • Revenue This Year
  • HOWL N/A
  • TLSA N/A
  • Revenue Next Year
  • HOWL $34.17
  • TLSA N/A
  • P/E Ratio
  • HOWL N/A
  • TLSA N/A
  • Revenue Growth
  • HOWL N/A
  • TLSA N/A
  • 52 Week Low
  • HOWL $1.26
  • TLSA $0.41
  • 52 Week High
  • HOWL $8.19
  • TLSA $1.74
  • Technical
  • Relative Strength Index (RSI)
  • HOWL 50.05
  • TLSA 64.21
  • Support Level
  • HOWL $1.28
  • TLSA $0.65
  • Resistance Level
  • HOWL $1.60
  • TLSA $0.70
  • Average True Range (ATR)
  • HOWL 0.11
  • TLSA 0.06
  • MACD
  • HOWL 0.03
  • TLSA 0.02
  • Stochastic Oscillator
  • HOWL 55.88
  • TLSA 98.77

About HOWL Werewolf Therapeutics Inc.

Werewolf Therapeutics Inc is a biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer. It is leveraging its proprietary PREDATOR platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. Its INDUKINE molecules are intended to remain inactive in peripheral tissue yet activate selectively in the tumor microenvironment or TME.

About TLSA Tiziana Life Sciences Ltd.

Tiziana Life Sciences Ltd is a clinical-stage biotechnology company that specializes in the developing transformative therapies for neurodegenerative and lung diseases. Its clinical pipeline includes drug assets for Secondary Progressive Multiple Sclerosis, ALS. Alzheimer's, Crohn's Disease and KRAS+ NSCLC. Tiziana is led by a team of qualified executives with extensive drug development and commercialization experience.

Share on Social Networks: